Enhancing oral delivery of plant-derived vesicles for colitis.

Autor: Liu Y; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of BioSciences, Rice University, Houston, TX 77005, USA. Electronic address: yliu32@mdanderson.org., Ahumada AL; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of BioSciences, Rice University, Houston, TX 77005, USA. Electronic address: ALankenau@mdanderson.org., Bayraktar E; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: EBayraktar@mdanderson.org., Schwartz P; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: Paul.Schwartz@tufts.edu., Chowdhury M; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: mamur@utexas.edu., Shi S; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Sebastian MM; Department of Veterinary Medicine and Surgery, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: MMSebastian@mdanderson.org., Khant H; Center for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Inc., Frederick, MD 21702, USA. Electronic address: htet.khant@nih.gov., de Val N; Center for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Inc., Frederick, MD 21702, USA. Electronic address: natalia.deval@thermofisher.com., Bayram NN; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: NNBayram@mdanderson.org., Zhang G; Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: GZhang3@mdanderson.org., Vu TC; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: TVu9@mdanderson.org., Jie Z; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jiezuliang@xmu.edu.cn., Jennings NB; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: nbjennin@mdanderson.org., Rodriguez-Aguayo C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: CRodriguez2@mdanderson.org., Swain J; Department of Veterinary Medicine and Surgery, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: JSwain@mdanderson.org., Stur E; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: EStur@mdanderson.org., Mangala LS; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: lsmangala@mdanderson.org., Wu Y; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nagaraju S; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: SNagaraju@mdanderson.org., Ermias B; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: be13@rice.edu., Li C; Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: CLi@mdanderson.org., Lopez-Berestein G; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: glopez@mdanderson.org., Braam J; Department of BioSciences, Rice University, Houston, TX 77005, USA. Electronic address: Braam@rice.edu., Sood AK; Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: asood@mdanderson.org.
Jazyk: angličtina
Zdroj: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2023 May; Vol. 357, pp. 472-483. Date of Electronic Publication: 2023 Apr 20.
DOI: 10.1016/j.jconrel.2023.03.056
Abstrakt: Plant-derived vesicles (PDVs) are attractive for therapeutic applications, including as potential nanocarriers. However, a concern with oral delivery of PDVs is whether they would remain intact in the gastrointestinal tract. We found that 82% of cabbage PDVs were destroyed under conditions mimicking the upper digestive tract. To overcome this limitation, we developed a delivery method whereby lyophilized Eudragit S100-coated cabbage PDVs were packaged into a capsule (Cap-cPDVs). Lyophilization and suspension of PDVs did not have an appreciable impact on PDV structure, number, or therapeutic effect. Additionally, packaging the lyophilized Eudragit S100-coated PDVs into capsules allowed them to pass through the upper gastrointestinal tract for delivery into the colon better than did suspension of PDVs in phosphate-buffered saline. Cap-cPDVs showed robust therapeutic effect in a dextran sulfate sodium-induced colitis mouse model. These findings could have broad implications for the use of PDVs as orally delivered nanocarriers of natural therapeutic plant compounds or other therapeutics.
Competing Interests: Declaration of Competing Interest A.K.S.: scientific consulting (Kiyatec, GSK, Merck, Onxeo, ImmunoGen, Iylon); shareholder (Biopath).
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: